Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.10
NYSE:IQV's Cash-to-Debt is ranked lower than
93% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. NYSE:IQV: 0.10 )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:IQV' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.1  Med: 0.31 Max: 0.51
Current: 0.1
0.1
0.51
Equity-to-Asset 0.35
NYSE:IQV's Equity-to-Asset is ranked lower than
82% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. NYSE:IQV: 0.35 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:IQV' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.55  Med: -0.16 Max: 0.41
Current: 0.35
-0.55
0.41
Debt-to-Equity 1.28
NYSE:IQV's Debt-to-Equity is ranked lower than
86% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. NYSE:IQV: 1.28 )
Ranked among companies with meaningful Debt-to-Equity only.
NYSE:IQV' s Debt-to-Equity Range Over the Past 10 Years
Min: -7.77  Med: -3.07 Max: 1.34
Current: 1.28
-7.77
1.34
Debt-to-EBITDA 5.95
NYSE:IQV's Debt-to-EBITDA is ranked lower than
89% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. NYSE:IQV: 5.95 )
Ranked among companies with meaningful Debt-to-EBITDA only.
NYSE:IQV' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.16  Med: 4.84 Max: 7.9
Current: 5.95
3.16
7.9
Interest Coverage 2.30
NYSE:IQV's Interest Coverage is ranked lower than
93% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. NYSE:IQV: 2.30 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:IQV' s Interest Coverage Range Over the Past 10 Years
Min: 2.3  Med: 3.67 Max: 6.71
Current: 2.3
2.3
6.71
Piotroski F-Score: 6
Altman Z-Score: 1.45
Beneish M-Score: -2.30
WACC vs ROIC
7.18%
20.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 8.46
NYSE:IQV's Operating Margin % is ranked higher than
62% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. NYSE:IQV: 8.46 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:IQV' s Operating Margin % Range Over the Past 10 Years
Min: 8.44  Med: 10.03 Max: 12.04
Current: 8.46
8.44
12.04
Net Margin % 13.07
NYSE:IQV's Net Margin % is ranked higher than
87% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. NYSE:IQV: 13.07 )
Ranked among companies with meaningful Net Margin % only.
NYSE:IQV' s Net Margin % Range Over the Past 10 Years
Min: 1.67  Med: 5.02 Max: 13.44
Current: 13.07
1.67
13.44
ROE % 16.86
NYSE:IQV's ROE % is ranked higher than
86% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.75 vs. NYSE:IQV: 16.86 )
Ranked among companies with meaningful ROE % only.
NYSE:IQV' s ROE % Range Over the Past 10 Years
Min: 2.85  Med: 9.25 Max: 16.86
Current: 16.86
2.85
16.86
ROA % 5.85
NYSE:IQV's ROA % is ranked higher than
77% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. NYSE:IQV: 5.85 )
Ranked among companies with meaningful ROA % only.
NYSE:IQV' s ROA % Range Over the Past 10 Years
Min: 0.92  Med: 8.14 Max: 20.82
Current: 5.85
0.92
20.82
ROC (Joel Greenblatt) % 162.15
NYSE:IQV's ROC (Joel Greenblatt) % is ranked higher than
97% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. NYSE:IQV: 162.15 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:IQV' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 160.05  Med: 226.96 Max: 338.36
Current: 162.15
160.05
338.36
3-Year Revenue Growth Rate 1.70
NYSE:IQV's 3-Year Revenue Growth Rate is ranked lower than
60% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. NYSE:IQV: 1.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:IQV' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 1.7 Max: 6.2
Current: 1.7
0
6.2
3-Year EBITDA Growth Rate 11.20
NYSE:IQV's 3-Year EBITDA Growth Rate is ranked higher than
54% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NYSE:IQV: 11.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:IQV' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 11.2 Max: 16
Current: 11.2
0
16
3-Year EPS without NRI Growth Rate 29.30
NYSE:IQV's 3-Year EPS without NRI Growth Rate is ranked higher than
76% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. NYSE:IQV: 29.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:IQV' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -24.6 Max: 30.4
Current: 29.3
0
30.4
GuruFocus has detected 3 Warning Signs with IQVIA Holdings Inc NYSE:IQV.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:IQV's 30-Y Financials

Financials (Next Earnings Date: 2018-08-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

IQV Guru Trades in

IQV Guru Trades in

Q4 2017

IQV Guru Trades in Q4 2017

Vanguard Health Care Fund 1,602,521 sh (New)
Pioneer Investments 277,293 sh (New)
Paul Tudor Jones 32,983 sh (New)
Jim Simons 523,047 sh (New)
Julian Robertson 261,100 sh (New)
Steve Mandel 9,868,332 sh (New)
Larry Robbins 8,576,935 sh (New)
Glenn Greenberg 482,866 sh (New)
Jana Partners 827,967 sh (New)
Ken Fisher 136,006 sh (New)
» More
Q1 2018

IQV Guru Trades in Q1 2018

John Hussman 30,000 sh (New)
Julian Robertson 272,700 sh (+4.44%)
Steve Mandel 9,890,932 sh (+0.23%)
Vanguard Health Care Fund 1,602,521 sh (unchged)
Glenn Greenberg Sold Out
Jana Partners Sold Out
Larry Robbins 7,719,983 sh (-9.99%)
Ken Fisher 117,901 sh (-13.31%)
Jim Simons 331,647 sh (-36.59%)
Pioneer Investments 156,983 sh (-43.39%)
Paul Tudor Jones 4,657 sh (-85.88%)
» More
» Details

Insider Trades

Latest Guru Trades with NYSE:IQV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Steve Mandel 2018-03-31 Add 0.23%0.01%$95.23 - $106.01 $ 101.761%9,890,932
Julian Robertson 2018-03-31 Add 4.44%0.15%$95.23 - $106.01 $ 101.761%272,700
Ken Fisher 2018-03-31 Reduce -13.31%$95.23 - $106.01 $ 101.761%117,901
Glenn Greenberg 2018-03-31 Sold Out 2.02%$95.23 - $106.01 $ 101.761%0
Steve Mandel 2017-12-31 New Buy5.04%$95 - $108.56 $ 101.76-0%9,868,332
Vanguard Health Care Fund 2017-12-31 New Buy0.34%$95 - $108.56 $ 101.76-0%1,602,521
Glenn Greenberg 2017-12-31 New Buy2.02%$95 - $108.56 $ 101.76-0%482,866
Julian Robertson 2017-12-31 New Buy3.99%$95 - $108.56 $ 101.76-0%261,100
Ken Fisher 2017-12-31 New Buy0.02%$95 - $108.56 $ 101.76-0%136,006
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621399    SIC: 8099
Compare:NYSE:A, TSE:6869, XSWX:LONN, NAS:IDXX, NYSE:LH, NYSE:DGX, XPAR:ERF, SZSE:300676, XTER:SRT3, XPAR:BIM, NYSE:PKI, NYSE:BIO, NYSE:QGEN, XAMS:PHIA, NAS:ICLR, NAS:DXCM, XTER:AFX, NAS:PRAH, NAS:EXAS, NYSE:CRL » details
Traded in other countries:QTS.Germany,
Headquarter Location:USA
IQVIA Holdings Inc is an information and technology-enabled healthcare service provider to the pharmaceutical services, biotechnology, and healthcare industries. The Commercial Solutions and Research and Development Solutions generate maximum revenue.

IQVIA was created from the merger of the healthcare data and analytics of IMS Health with the global contract research organization powerhouse of Quintiles. The CRO segment focuses primarily on providing outsourced phase 2-4 clinical trials for pharmaceutical, device, and diagnostic companies. The legacy IMS business provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers.

Top Ranked Articles about IQVIA Holdings Inc

Glenn Greenberg's Top Trades in 1st Quarter Nielsen grabs 10% of a concentrated portfolio while JPMorgan Chase and Charles Schwab Corp get trimmed
Glenn Greenberg (Trades, Portfolio)'s Brave Warrior Advisors initiated a new position as part of a concentrated portfolio of 13 stocks in the early months of the year. Read more...
Market Trends Toward New Normal in FormFactor, Corindus Vascular Robotics, Syntel, IQVIA Holdings, Hannon Armstrong Sustainable Infrastructure Capital, and Ennis — Emerging Consolidated Expectations, Analyst Ratings
MDA Collaborates with IQVIA to Expand Disease Registry into the New MOVR Data Hub
Steve Mandel Expands Reach in Health Care Space With Exact Sciences Guru takes an interest in medical diagnostics company
Lone Pine Capital leader Steve Mandel (Trades, Portfolio) disclosed this week he established a 5.3% stake in Exact Sciences Corp. (NASDAQ:EXAS) on Feb. 23, expanding his positioning in the health care space. Read more...
Tiger Management Buys eBay, IQVIA, Comcast Firm's largest buys of the 4th quarter
Tiger Management was founded by Julian Robertson (Trades, Portfolio) in 1980. The firm increased several holdings and established many other positions in the fourth quarter. Read more...
Steve Mandel Takes an Interest in IQVIA Holdings Hedge fund releases 4th-quarter portfolio
Lone Pine Capital founder Steve Mandel (Trades, Portfolio) disclosed his fourth-quarter portfolio on Feb. 14, listing eight new positions. Read more...
Larry Robbins' Top 5 New Buys in 4th Quarter Glenview Capital drops nearly $1 billion on IQVIA Holdings
Glenview Capital Management CEO Larry Robbins (Trades, Portfolio) picked up nine new stocks in the fourth quarter, his firm reported Friday. Read more...
Cota Announces $40 Million Series C Financing to Advance its Cota Nodal Address™ Classification System and Real-World Evidence and Analytics Platforms
Glenn Greenburg Establishes 3 Positions in 4th Quarter Top buy is Google parent Alphabet Inc
Glenn Greenburg, manager of Brave Warrior Advisors, disclosed Feb. 14 he initiated three positions during fourth-quarter 2017: Alphabet Inc. (NASDAQ:GOOGL), IQVIA Holdings Inc. (NYSE:IQV) and Express Scripts Holding Co. (NASDAQ:ESRX). Read more...
Vanguard Health Care Fund Buys Danaher, CVS Health, Adds to Allergan The fund's largest buys of the 4th quarter
The Vanguard Health Care Fund (Trades, Portfolio) increased many holdings and established several other positions in the fourth quarter. The fund's nine largest trades are as follows: Read more...

Ratios

vs
industry
vs
history
PE Ratio 17.29
IQV's PE Ratio is ranked higher than
81% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. IQV: 17.29 )
Ranked among companies with meaningful PE Ratio only.
IQV' s PE Ratio Range Over the Past 10 Years
Min: 16.04  Med: 23.81 Max: 307.21
Current: 17.29
16.04
307.21
Forward PE Ratio 19.01
IQV's Forward PE Ratio is ranked higher than
77% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. IQV: 19.01 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 17.29
IQV's PE Ratio without NRI is ranked higher than
81% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. IQV: 17.29 )
Ranked among companies with meaningful PE Ratio without NRI only.
IQV' s PE Ratio without NRI Range Over the Past 10 Years
Min: 16.04  Med: 23.81 Max: 307.21
Current: 17.29
16.04
307.21
Price-to-Owner-Earnings 25.83
IQV's Price-to-Owner-Earnings is ranked higher than
88% of the 76 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 36.75 vs. IQV: 25.83 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
IQV' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 14.92  Med: 26.29 Max: 35.4
Current: 25.83
14.92
35.4
PB Ratio 2.56
IQV's PB Ratio is ranked higher than
71% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. IQV: 2.56 )
Ranked among companies with meaningful PB Ratio only.
IQV' s PB Ratio Range Over the Past 10 Years
Min: 2.02  Med: 2.54 Max: 3.2
Current: 2.56
2.02
3.2
PS Ratio 2.20
IQV's PS Ratio is ranked higher than
67% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. IQV: 2.20 )
Ranked among companies with meaningful PS Ratio only.
IQV' s PS Ratio Range Over the Past 10 Years
Min: 1.07  Med: 1.53 Max: 2.58
Current: 2.2
1.07
2.58
Price-to-Free-Cash-Flow 30.93
IQV's Price-to-Free-Cash-Flow is ranked lower than
63% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. IQV: 30.93 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
IQV' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 14.11  Med: 22.32 Max: 73.02
Current: 30.93
14.11
73.02
Price-to-Operating-Cash-Flow 20.19
IQV's Price-to-Operating-Cash-Flow is ranked lower than
59% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. IQV: 20.19 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
IQV' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.19  Med: 17.38 Max: 35.99
Current: 20.19
12.19
35.99
EV-to-EBIT 44.35
IQV's EV-to-EBIT is ranked lower than
81% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. IQV: 44.35 )
Ranked among companies with meaningful EV-to-EBIT only.
IQV' s EV-to-EBIT Range Over the Past 10 Years
Min: 13.7  Med: 17.2 Max: 49.6
Current: 44.35
13.7
49.6
EV-to-EBITDA 17.54
IQV's EV-to-EBITDA is ranked higher than
58% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. IQV: 17.54 )
Ranked among companies with meaningful EV-to-EBITDA only.
IQV' s EV-to-EBITDA Range Over the Past 10 Years
Min: 11.5  Med: 13.9 Max: 27.3
Current: 17.54
11.5
27.3
EV-to-Revenue 3.08
IQV's EV-to-Revenue is ranked higher than
62% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. IQV: 3.08 )
Ranked among companies with meaningful EV-to-Revenue only.
IQV' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.3  Med: 1.8 Max: 3.6
Current: 3.08
1.3
3.6
PEG Ratio 1.31
IQV's PEG Ratio is ranked higher than
77% of the 48 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.26 vs. IQV: 1.31 )
Ranked among companies with meaningful PEG Ratio only.
IQV' s PEG Ratio Range Over the Past 10 Years
Min: 0.56  Med: 0.71 Max: 1.31
Current: 1.31
0.56
1.31
Current Ratio 1.16
IQV's Current Ratio is ranked lower than
86% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. IQV: 1.16 )
Ranked among companies with meaningful Current Ratio only.
IQV' s Current Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.35 Max: 1.65
Current: 1.16
1.15
1.65
Quick Ratio 1.16
IQV's Quick Ratio is ranked lower than
75% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. IQV: 1.16 )
Ranked among companies with meaningful Quick Ratio only.
IQV' s Quick Ratio Range Over the Past 10 Years
Min: 1.15  Med: 1.35 Max: 1.65
Current: 1.16
1.15
1.65
Days Sales Outstanding 82.29
IQV's Days Sales Outstanding is ranked higher than
72% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. IQV: 82.29 )
Ranked among companies with meaningful Days Sales Outstanding only.
IQV' s Days Sales Outstanding Range Over the Past 10 Years
Min: 55.92  Med: 66.15 Max: 90.59
Current: 82.29
55.92
90.59
Days Payable 116.08
IQV's Days Payable is ranked lower than
92% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. IQV: 116.08 )
Ranked among companies with meaningful Days Payable only.
IQV' s Days Payable Range Over the Past 10 Years
Min: 8.02  Med: 10.03 Max: 116.08
Current: 116.08
8.02
116.08

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -18.80
IQV's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. IQV: -18.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IQV' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -22  Med: 2.2 Max: 0
Current: -18.8
-22
0

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.99
IQV's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
56% of the 75 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.41 vs. IQV: 1.99 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
IQV' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.91  Med: 2.04 Max: 2.13
Current: 1.99
1.91
2.13
Price-to-Median-PS-Value 1.44
IQV's Price-to-Median-PS-Value is ranked lower than
78% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. IQV: 1.44 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IQV' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.76  Med: 1.01 Max: 1.48
Current: 1.44
0.76
1.48
Price-to-Peter-Lynch-Fair-Value 0.85
IQV's Price-to-Peter-Lynch-Fair-Value is ranked higher than
77% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. IQV: 0.85 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
IQV' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.65  Med: 0.74 Max: 0.86
Current: 0.85
0.65
0.86
Earnings Yield (Greenblatt) % 2.25
IQV's Earnings Yield (Greenblatt) % is ranked higher than
64% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. IQV: 2.25 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IQV' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2  Med: 5.8 Max: 7.3
Current: 2.25
2
7.3
Forward Rate of Return (Yacktman) % 22.92
IQV's Forward Rate of Return (Yacktman) % is ranked higher than
71% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.45 vs. IQV: 22.92 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
IQV' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 16.9  Med: 21.95 Max: 23.2
Current: 22.92
16.9
23.2

More Statistics

Revenue (TTM) (Mil) $9,980.00
EPS (TTM) $ 5.88
Beta0.63
Volatility18.57%
52-Week Range $83.16 - 110.67
Shares Outstanding (Mil)207.14

Analyst Estimate

Dec18 Dec19 Dec20
Revenue (Mil $) 10,165 10,681 9,583
EBIT (Mil $) 1,477 1,658 2,275
EBITDA (Mil $) 2,152 2,333 2,549
EPS ($) 5.38 6.18 6.69
EPS without NRI ($) 5.38 6.18 6.69
EPS Growth Rate
(Future 3Y To 5Y Estimate)
13.04%
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 66
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyY
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}